UNITAID The HIV/AIDS Medicines Patent Pool Initiative Overview

Similar documents
UNITAID s approach to funding innovations in TB diagnosis and treatment Robert Matiru & Janet Ginnard, UNITAID Geneva, 29 April 2015

Access to current products and innovation for the future- Some community Thoughts. Kenly Sikwese Geneva 1 November 2011

Draft Plan of Action Chair's Text Status 3 May 2008

Elements of a global strategy and plan of action

Formation and Management

1. Recognizing that some of the barriers that impede the diffusion of green technologies include:

Intellectual Property

Protecting Intellectual Property under TRIPS, FTAs and BITs: Conflicting Regimes or Mutual Coherence?

Alternatives to Ex Ante Disclosure

A POLICY in REGARDS to INTELLECTUAL PROPERTY. OCTOBER UNIVERSITY for MODERN SCIENCES and ARTS (MSA)

Global strategy and plan of action on public health, innovation and intellectual property

Standing Committee on the Law of Patents Twenty-Sixth Session

APEC Internet and Digital Economy Roadmap

Topic 2: Patent-related Flexibilities in Multilateral Treaties and Their Importance for Developing Countries and LDCs

UNCITRAL Third International Colloquium on Secured Transactions Session on Contractual Guide on IP Licensing (Vienna, March 3, 2010)

HIV and co-infection medicines

Discovery: From Concept to the Patient - The Business of Medical Discovery. Todd Sherer, Ph.D.

Intellectual Property Policy. DNDi POLICIES

An Essential Health and Biomedical R&D Treaty

TRAINING SEMINAR PHARMACEUTICALS AND INTELLECTUAL PROPERTY ACCESS TO MEDICINE: Exploitation of pharmaceutical patents: compulsory licences SESSION 4

WIPO-WTO Colloquium for Teachers of Intellectual Property

Investing in Mercy January 2017

Access to Medicines, Patent Information and Freedom to Operate

Medical Innovation Changing Business Models. Geneva, 5 July 2013

IPRs and Public Health: Lessons Learned Current Challenges The Way Forward

The 45 Adopted Recommendations under the WIPO Development Agenda

INSTITUTE OF MEDICINE COMMITTEE ON THE U.S. COMMITMENT TO GLOBAL HEALTH

Implementing Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property in the Eastern Mediterranean Region

Sustainable development

IS STANDARDIZATION FOR AUTONOMOUS CARS AROUND THE CORNER? By Shervin Pishevar

Engaging Industry Partners

Dr. Biswajit Dhar Professor, Jawaharlal Nehru University, India and Member DA9 Advisory Board

The high cost of standardization How to reward innovators

Draft global strategy on public health, innovation and intellectual property

African Civil Society Meeting

SHORT SUMMARY REPORT OF THE WORKSHOP ON GENETIC INVENTIONS, INTELLECTUAL PROPERTY RIGHTS AND LICENSING PRACTICES

Using Academic Licensing Agreements to Promote Global Social Responsibility

Patent Pools Assessing Their Value-Added for Global Health Innovation and Access. Rebecca Goulding and Amrita Palriwala

Patent Pools. Assessing Their Value-Added for Global Health Innovation and Access. Rebecca Goulding and Amrita Palriwala

WIPO Development Agenda

Facilitating SEP Licensing -JPO's Approach- March 13, 2018 Naoko MUNAKATA Commissioner of the Japan Patent Office

WORLD TRADE ORGANIZATION ADVANCED COURSE. WIPO-WTO/ADV/ACAD/13/INF1.PROV ORIGINAL: English DATE: XXXX

April 21, By to:

exceptional circumstance:

TRIPS FLEXIBILITIES AND ACCESS TO MEDICINES

Intellectual Property Management Medicines for Malaria Venture. Life Sciences Symposium WIPO 15 December 2008

Other Transaction Agreements. Chemical Biological Defense Acquisition Initiatives Forum

Fixing Canada s Access to Medicines Regime (CAMR): 20 Questions & Answers

Intellectual Property & Technology Transfer

Setting out the EU approach to Standard Essential Patents:

Standard-Essential Patents

HEVC Patent Portfolio License Briefing*

EXECUTIVE BOARD MEETING METHODOLOGY FOR DEVELOPING STRATEGIC NARRATIVES

Regional Seminar on the Effective Implementation and Use of Several Patent-Related Flexibilities

AAAS Project on Science and Intellectual Property in the Public Interest

COLLABORATIVE R&D & IP ISSUES IN TECHNOLOGY TRANSFER IN UNIVERSITY SYSTEM

Flexibilities in the Patent System

BIPF Munich. South Africa Enforcement of Pharmaceutical Patents and the New Draft IP Policy

TRIPs & PATENTS. In 1899, Mr. Charles H. Duell, Director of US Patent office said Everything that can be invented, has (already) been invented.

Standing Committee on the Law of Patents

Enforcement of Intellectual Property Rights Frequently Asked Questions

Compulsory Licensing:

TRIPS and Access to Medicines. The Story so far

Conference. Intellectual property and sustainable development: what are the winning initiatives?

31 August Background

The stakes within diverse global policy deliberations concerning treatment of Intellectual Property related to standard-setting

Practical Strategies for Biotechnology and Medical Device Companies to Manage Intellectual Property Rights

WIPO Sub-Regional Workshop on Patent Policy and its Legislative Implementation

Topic 2: The Critical Role of IP Policies in Modern Economies

9/27/2013. Office of Technology Transfer Overview. Impacts from NC State Technology Transfer. NC State s Office of Technology Transfer

Intellectual Property Ownership and Disposition Policy

Americas Trade and Sustainable Development Forum (ATSDF) November 2003, Miami. Trade, Knowledge and Intellectual Property Rights Thematic Tent

eskbook Emerging Life Sciences Companies second edition Chapter 8 Checklist for Planning and Conducting an Effective FTO Search

The TRIPS Tightrope public health, innovation, incentives and access

THE WIPO DEVELOPMENT AGENDA. New York February 2011

SEMINAR: INTELLECTUAL PROPERTY ARRANGEMENTS: IMPLICATIONS FOR DEVELOPING COUNTRY PRODUCTIVE CAPABILITIES IN THE SUPPLY OF ESSENTIAL MEDICINES.

Standing Committee on the Law of Patents

Guidelines on Standardization and Patent Pool Arrangements

Pan-Canadian Trust Framework Overview

Latin-American non-state actor dialogue on Article 6 of the Paris Agreement

_prop_lab_partner.htm

Comments on the Commission s draft Guidelines on the application of Article 101 TFEU on technology transfer agreements

What Do You Do When Your Board of Directors Wants to Monetize Your Intellectual Property Assets?

Regional Seminar for Certain African Countries on the Implementation and Use of Several Patent-Related Flexibilities

Virtual Mentor American Medical Association Journal of Ethics December 2006, Volume 8, Number 12:

TRIPS, FTAs and BITs: Impact on Domestic IP- and Innovation Strategies in Developing Countries

UN GA TECHNOLOGY DIALOGUES, APRIL JUNE

INTRODUCTION Standards have become the foundation for information exchange, communications, and entertainment. Today, as in the past, governments deve

Intellectual Property Protection. Jeffrey S. Newman May 14, 2013

STRATEGIC ORIENTATION FOR THE FUTURE OF THE PMR:

WHO workshop on IP and Vaccines. Geneva 19 th -20 th April Introduction to the IP issues Christopher Garrison Consultant to WHO

B) Issues to be Prioritised within the Proposed Global Strategy and Plan of Action:

AIDS). Director, Infectious Disease Division, Pistoia Hospital, Pistoia, Italy

Brief to the. Senate Standing Committee on Social Affairs, Science and Technology. Dr. Eliot A. Phillipson President and CEO

The Standardization and the Patent Issue in Telemedicine

Rosatom Approach to IPR Management in Collaborative Projects on Innovations

Statement by the BIAC Committee on Technology and Industry on THE IMPACT OF INTELLECTUAL PROPERTY PROTECTION ON INNOVATION AND TECHNOLOGY DEVELOPMENT

Role of Patents in Green Technology Transfer in the Context of Climate Change

WHO'S MINDING THE STORE: STOPPING YOUR IP FROM GOING OUT THE FRONT (& BACK) DOOR

Transferring UCLA discoveries to the public. Kathryn Atchison, DDS, MPH Vice Provost, Associate Vice Chancellor for Research

Transcription:

UNITAID The HIV/AIDS Medicines Patent Pool Initiative Overview December 2009

UNITAID Mission UNITAID's Mission Scale up access to treatment for HIV/AIDS, malaria and TB Leverage price reductions of quality drugs and diagnostics Accelerate availability How Sustainable, predictable and additional funding to generate a steady demand for drugs and diagnostics Impact market dynamics to reduce prices and increase availability and supply Support the Doha Declaration on TRIPS and Public Health Any other innovative solution that may overcome limitations to market diversification in developing countries will also be pursued

What is a Patent Pool? What is a Patent Pool? Portfolio of patents and other relevant intellectual property held by various actors made available on a non exclusive basis to third parties, (e.g. generic manufacturers) against the payment of royalties. Patent Pools come in different shapes and forms and are set up for different purposes While we learn from existing 'standards' pool, the Medicines Patent Pool Initiative is quite different

History of Medicines Patent Pool 2006 2008 2009 CIPIH 2006 recommendation: "Patent pools of upstream technologies may be useful in some circumstances to promote innovation relevant to developing countries. and May 2008 WHO Global Strategy and Plan of Action included Voluntary Patent Pools July 2008 UNITAID Executive Board Green light 'to establish a voluntary medicines patent pool Broad stakeholder consultation Developed the implementation plan for the medicines patent pool Ongoing dialogue on terms and conditions Proposed to UNITAID to set up a medicines patent pool.

Public Health Vision and the Medicines Patent Pool Mission Public Health Vision To improve access to appropriate affordable antiretrovirals in developing countries Medicines Patent Pool Mission The patent pool will bring down the prices of HIV drugs, facilitate the development and production of improved formulations (e.g. fixed dose combinations and drugs for children) by providing access to intellectual property relating to these products

13 Guiding Principles of the Medicines Patent Pool 13 Guiding Principles of the Medicines Patent Pool 1. Public health driven: The Patent Pool will be driven by public health needs 2. ARV focus: The Patent Pool will initially focus on antiretroviral (ARVs) medicines 3. Voluntary: The Patent Pool will operate on a voluntary basis 4. Developing country focus: The Patent Pool will focus on developing countries (low and middle income countries as classified by the World Bank) 5. Price reductions: The Patent Pool will focus on achieving price reductions through increased competition for production & distribution 6. Enable product development: The Patent Pool will enable "access to patents" to facilitate the development of appropriate and adapted formulations 7. Flexible: The Patent Pool will be sufficiently flexible and innovative to adapt to evolving health needs and opportunities 8. Quality assurance: The Patent Pool will leverage existing mechanisms (e.g. WHO pre qualification, US FDA, EMEA) for quality assurance 9. Standardized licenses: Key license terms and conditions will be standardized across all licensees / licensors to ensure efficiency and effectiveness 10. Non discriminatory licenses: Licenses will be available on a non exclusive and nondiscriminatory basis in order to enhance competition 11. Additional: The Patent Pool will be additional to other mechanisms and measures to promote access to medicines 12. Intellectual Property: The Patent pool will operate within the current IP framework. Patent owners will be compensated through royalties as appropriate. The patent pool will manage products rather than specific underlying patents 13. Independent entity: The Entity administering the Patent Pool must be independent

How will the Patent Pool help to address impending patent related access problems? Diversifying supply sources to reduce prices Expanding generic market size to reduce prices & expand access Facilitating the development of improved formulations (e.g. Fixed Dose Combinations (FDCs), pediatric and heat stable formulations) Increasing legal certainty for generic companies and patent holders Reducing transaction costs for licensing agreements (e.g. FDCs)

How will the Patent Pool operate? Patent Pool entity works with WHO to identify products of interest in relevant countries Patent Pool entity develops standardized licensing agreement with patent holder Patent holder licenses product to Patent Pool entity Patent Pool entity sublicenses product to licensee Licensee produce products for countries in scope Licensee produce reports for patent holders and Patent Pool entity regarding products sold, price, country of sale, etc. Licensee pays royalties directly to patent holder Patent Pool entity works with key stakeholder to identify potential incentives necessary to achieve the mission of the patent pool

How will the Patent Pool operate? Patent Pool negotiates standard license agreements with patent holders. Generic manufacturers interact directly with the patent owners for royalty payments. NGOs UNITAID WIPO WHO 2 6 Donors 1 Patent Pool 9 Entity License Patent 3 7 8 10 Sub license Patent Licensors 4 5 $ Pay Royalties Licensees 1 Identifying Products of Interest in Relevant Countries 3 Developing / Managing Licensing Agreements 5 Compliance / Auditing 7 Performance Management 9 Incentive Management 2 Recruiting Potential Licensors / Licensees of Patent Pool 4 Royalty Management 6 Dispute Resolution 8 Communications 10 Stakeholder Management * Refer to Appendix for details of the patent pool functions

Next steps... Continued consultations with patent holders to refine the proposed terms and conditions Continued engagement with potential sub licensees Establish legal entity for the UNITAID Patent Pool Commence formal negotiations Conclude agreements

Thank You!